{"created":"2023-06-19T08:41:35.782734+00:00","id":9122,"links":{},"metadata":{"_buckets":{"deposit":"0f012bc4-59b9-4416-aacc-b767096d3c79"},"_deposit":{"created_by":2,"id":"9122","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"9122"},"status":"published"},"_oai":{"id":"oai:gunma-u.repo.nii.ac.jp:00009122","sets":["719:760:761:815"]},"author_link":["37327","37335","37324","37326","37336","37328","37325","37329","37330","37334","37333","37331","37332"],"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-08-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"156","bibliographicPageStart":"151","bibliographicVolumeNumber":"68","bibliographic_titles":[{"bibliographic_title":"The Kitakanto medical journal = 北関東医学"}]}]},"item_6_date_61":{"attribute_name":"更新日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2019-12-04","subitem_date_issued_type":"Created"}]},"item_6_description_39":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background and Aims: Radioimmunotherapy (RIT) appears as one of the most effective treatment options for patientswith relapsed or resistant non-Hodgkin’s lymphoma (NHL).　Our aim was to evaluate the role of pre-RIT 18F-fluorodeoxyglucose-positron emission tomography╱computed tomography (FDG-PET╱CT) as an early predictor of 90Y-Ibritumomabtiuxetan treatment response.　Methods: We included consecutive 20 patients with relapsed NHL (10 males; meanage, 58.5 ± 8.9 years old) who were treated with 90Y-Ibritumomab tiuxetan.　FDG-PET╱CT was performed before andafter treatment.　Semiquantitative parameters of all measurable FDG-avid lesions were measured and averaged.　Ameasurable FDG-avid lesion was defined as a lesion that showed FDG uptake higher than liver with a diameter morethan 1 cm.　Treatment response was determined by visual assessment based on a five-point score criteria from FDGPET╱CT after treatment.　Results: Fourteen patients (70%) were classified as responders and the other six patients(30%) as non-responders.　All semiquantitative parameters except for MTV demonstrated significantly lower values inthe responders compared with the non-responders (p＜0.05).　Conclusions: Semiquantitative evaluation by SUVmax,SUVpeak, and TLG before treatment were useful as early predictors of 90Y-Ibritumomab tiuxetan treatment response.","subitem_description_type":"Abstract"}]},"item_6_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"北関東医学会"}]},"item_6_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1343-2826","subitem_source_identifier_type":"ISSN"}]},"item_6_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN10585677","subitem_source_identifier_type":"NCID"}]},"item_6_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yudistiro, Ryan"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Heryanto, Yusri Dwi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kodaira, Sayaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Higuchi, Tetsuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Arisaka, Yukiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tokue, Azusa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Taketomi-Takahashi, Ayako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsukamoto, Norifumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yokohama, Akihiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Handa, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koiso, Hiromi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ishizaki, Takuma"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsushima, Yoshiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-01-08"}],"displaytype":"detail","filename":"68_151.pdf","filesize":[{"value":"459.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"68_151.pdf","url":"https://gunma-u.repo.nii.ac.jp/record/9122/files/68_151.pdf"},"version_id":"8a6bdc29-c333-44c5-9f0b-bc12619c7360"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"non-Hodgkin lymphoma","subitem_subject_scheme":"Other"},{"subitem_subject":"radioimmunotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"90Y-Ibritumomab tiuxetan","subitem_subject_scheme":"Other"},{"subitem_subject":"FDG-PET╱CT","subitem_subject_scheme":"Other"},{"subitem_subject":"response predictor","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response"}]},"item_type_id":"6","owner":"2","path":["815"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-12-03"},"publish_date":"2019-12-03","publish_status":"0","recid":"9122","relation_version_is_last":true,"title":["Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of 90Y-Ibritumomab Tiuxetan Response"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-06-19T10:09:06.382045+00:00"}